Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Paul Edick Insider Profile
11 Followers
Paul Edick, Director at Lumos Pharma, holds 7.91K shares in Lumos Pharma (Ticker: LUMO), holds ― shares in Neos Therapeutics (Ticker: NEOS), holds 3.82M shares in Xeris Pharmaceuticals (Ticker: XERS).
Profitable Transactions
3 out of 10 Profitable Transactions
Average Return
-10.60%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Paul Edick holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Buy
Date:May 13, 2022 - May 13, 2023
Return:+69.50%
The most profitable trade made by Paul Edick
Paul Edick's Trading History
Lumos Pharma
May 04, 2015
Director
Uninformative Buy
―
$23.88K
Neos Therapeutics
―
―
―
―
Sucampo Pharmaceuticals
Feb 13, 2018
―
Uninformative Sell
268.74K
$0.00
Xeris Pharmaceuticals
Jan 31, 2024
Chairman and CEO, Director
Uninformative Buy
―
$6.69M
Iterum Therapeutics
May 29, 2019
Director
Uninformative Buy
―
$49.91K
Milestone Pharmaceuticals
―
Director
―
―
PDL BioPharma
Jun 12, 2018
―
Uninformative Buy
150.00K
$529.97K
Durata
Nov 18, 2014
―
Uninformative Sell
―
―
List of latest transactions for each holding click on a transaction to see Paul Edick's performance on stock
You May Also Like
Paul Edick insider profile FAQ
What is the percentage of profitable transactions made by Paul Edick?
The percentage of profitable transactions made by Paul Edick is 30%.
What is the average return per transaction made by Paul Edick?
The average return per transaction made by Paul Edick is -10.60%.
What stocks does Paul Edick hold?
Paul Edick holds: LUMO, NEOS, SCMP, XERS, ITRM, MIST, PDLI, DRTX stocks.
What was Paul Edick’s latest transaction?
Paul Edick latest transaction was an Uninformative Buy of ―.
What was Paul Edick's most profitable transaction?
Paul Edick’s most profitable transaction was an Informative Buy of XERS stock on May 13, 2022. The return on the trade was 69.50%.
What is Paul Edick's role in Lumos Pharma?
Paul Edick's role in Lumos Pharma is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.